Clinical Trial Update: Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating quetiapine fumarate (SEROQUEL) versus placebo in generalized anxiety disorder has completed, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• SEROQUEL (QUETIAPINE)

Snippet

Sponsor: AstraZeneca | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: COMPLETED